Biological Priming Protocol: Systemic Tuning of Physiology to Optimize Neuroplasticity

Introduction to the Paradigm of Biological Priming and Neuroplasticity

The ability of the brain's neural networks to continuously reorganize, form new synaptic connections, and structurally adapt to the dynamic demands of the internal and external environment is defined in modern neurobiology as neuroplasticity. In clinical, academic, and fundamental neurobiology, the emphasis is traditionally placed on the final behavioral, cognitive, or pharmacological triggers of plasticity. However, growing bodies of translational data indicate that the effectiveness of any neuroplastic interventions—from intensive motor learning and computerized cognitive training to therapy with powerful psychoplastogens (such as psilocybin, dimethyltryptamine, or ketamine)—is fundamentally limited by the baseline state of the cellular microenvironment, metabolic status, and neuroendocrine reactivity of the patient's organism.

Biological priming is a strictly calibrated, scientifically grounded protocol of targeted, stepwise preparation of the physiological substrate prior to the induction of structural changes in the central nervous system (CNS). The essence of the priming concept lies in shifting the CNS from a state of homeostatic rigidity, energy deficit, or neuroinflammatory stress into a so-called permissive state of heightened susceptibility. This is achieved through synergistic, chronologically aligned modulation of membrane fluidity, mitochondrial function, expression of neurotrophic factors (primarily brain-derived neurotrophic factor, BDNF), and optimization of glymphatic clearance.

The concept of biological priming also relies on the principles of Bienenstock-Cooper-Munro (BCM) homeostatic metaplasticity. According to this model, a preliminary reduction or alteration of the corticospinal excitability threshold using one protocol (e.g., aerobic exercise or a specific dietary intervention) induces stronger facilitating effects during the subsequent application of the primary neuroplasticity protocol. Ignoring these mechanisms and early preparatory phases (e.g., failing to resolve systemic inflammation) can completely negate the effects of later triggers, such as exercise-induced BDNF release, which is frequently observed in patients with obesity or metabolic syndrome.

Furthermore, the lack of a prepared physiological foundation can lead to the phenomenon of "negative neuroplasticity." Moderate to severe chronic traumatic brain injuries, as well as prolonged exposure to environmental impoverishment, trigger a downward spiral of maladaptive neuroplastic changes that accelerate cognitive aging, induce brain volume loss, and compromise white matter integrity. Thus, systemic biological priming is aimed not only at amplifying positive reorganization but also at preventing the fixation of pathogenic synaptic patterns. A comprehensive analysis of open neurobiological data allows for the construction of a strict chronological physiological tuning scheme, divided into mutually complementary phases.

Phase 1: Lipid Reorganization of Membranes and Suppression of the Neuroinflammatory Microenvironment (T-minus 8 weeks)

Any changes in synaptic architecture require a colossal amount of physical building material and adequate fluidity of neuronal membranes. Without a proper lipid foundation, the conformation of membrane receptors, the efficiency of ion channels, and the vesicular transport of neurotransmitters remain suboptimal, blocking signal transmission at the very earliest stages.

The Quantum and Structural Role of Polyunsaturated Fatty Acids (PUFAs)

Omega-3 polyunsaturated fatty acids, particularly docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids, are obligate structural components of neuronal membranes and are absolutely indispensable for their synthesis. DHA quantitatively dominates among all long-chain PUFAs in the brain and specifically accumulates in areas critically important for learning, spatial memory, and neurogenesis, such as the cerebral cortex and hippocampus. The presence of sufficient DHA in the erythrocytes of middle-aged individuals (40-50 years) is reliably associated with the preservation of hippocampal volume and the improvement of cognitive markers of brain aging, as confirmed by MRI scanning and testing data.

The physiological integration of Omega-3 into brain tissue is an exceptionally slow metabolic process. While EPA levels in erythrocytes reflect recent intake (within a few days) and depend on rapid exchange with plasma lipoproteins, the enrichment of internal cellular neuronal membranes with DHA requires a long time due to the slow turnover of erythrocytes and specific transport across the blood-brain barrier. In the event of dietary DHA deficiency, the central nervous system triggers a mechanism known as "homeoviscous compensation." In an attempt to maintain a constant degree of unsaturation and fluidity of the phospholipid membrane, the brain replaces the missing DHA with docosapentaenoic acid ($DPAn-6$). However, this structural surrogate substitution leads to profound disruptions of membrane properties, altered enzymatic activity, and radical modification of the electrophysiological characteristics of neurons.

An innovative biophysical hypothesis explaining the indispensable nature of DHA suggests that the unique spatial structure of this molecule with its six double bonds enables the quantum transfer and communication of $\pi$-electrons through the depth of the cell membrane. This quantum mechanism offers an explanation for the ultra-precise depolarization of retinal membranes and highly organized, cohesive neuronal signaling, which is a fundamental condition for higher cognitive functions and intelligence.

DHA is predominantly esterified at the sn-2 position of membrane glycerophospholipids, from where it can be released by the action of specific phospholipase A2 (PLA2) enzymes activated by neurotransmitter receptors. Once released, DHA and its bioactive derivatives act as secondary messengers, regulating signal transduction pathways. Animal model studies demonstrate that significant changes in neuronal phospholipid composition require continuous supplementation. For instance, oral administration of 300 mg/kg/day of DHA or EPA to gerbils for 8 weeks induces multiple changes, including the production of new species of phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylethanolamine (PE), and phosphatidylcholine (PC).

The synthesis and accumulation of phosphatidylserine (PS) in neuronal tissues are critically sensitive to membrane DHA levels. DHA at the sn-2 position of the phosphatidylcholine molecule is most favorably converted into PS via serine base exchange. An increase in PS content in neuronal membranes triggers the PI3-kinase/Akt signaling pathway, which is one of the primary cascades ensuring neuronal survival, stimulating myelinogenesis, and inhibiting apoptosis.

Moreover, the accumulation of DHA directly and potently correlates with:

• A reliable increase in the levels of critical presynaptic and postsynaptic proteins: syntaxin-3 (a crucial factor in neuronal growth and regeneration), PSD-95 (postsynaptic density), and synapsin-1. Importantly, these neuroplastic effects are not observed with alternative arachidonic acid (AA) treatment.
• Modulation of receptor expression. Omega-3 PUFA deficiency is associated with altered expression of $5-HT_{1A}$ and $\alpha_{2A}$-adrenoreceptors, leading to aberrant behavioral activation (e.g., pathological responses in forced swim tests in rodents) and neurotransmission disorders.
• Regulation of the Gut-Brain Axis (GBA). DHA and EPA modulate the function of this axis by strengthening intestinal barriers, enhancing systemic immunity through their impact on the microbiome, and regulating the hypothalamic-pituitary-adrenal (HPA) axis by reducing excess cortisol production in response to stress.

Reprogramming of Reactive Astrocytes and Neuroinflammation

Astrogliosis—a process of pathological hypertrophy and proliferation of astrocytes in response to micro-injuries, systemic infections, or chronic oxidative stress—is considered one of the primary markers of brain aging and neurodegeneration, found in elderly rodents and humans. Under conditions of ischemia, traumatic brain injury, or age-related decline in blood circulation, reactive astrocytes alter their morphology, retracting the endfeet that contact blood vessels, leading to a direct disruption of blood-brain barrier (BBB) integrity.

In such a reactive phenotype, astrocytes begin to massively produce pro-inflammatory cytokines (IL-1$\beta$, TNF-$\alpha$, IL-6) and reactive oxygen species (ROS), while simultaneously fatally reducing the necessary trophic support for neurons (secretion of BDNF and GDNF), thereby exacerbating degeneration. Chronic systemic inflammation associated with, for example, visceral obesity or metabolic syndrome, directly impedes the realization of neuroplastic potential by disrupting BDNF signaling pathways and reducing exercise-induced neuroplastic responses. Metabolic remodeling caused by the activation of the NF-$\kappa$B pathway also reduces lactate production by astrocytes, depriving neurons of critical metabolic support.

To transition astrocytes back into a neuroprotective, trophic phenotype in Phase 1, a strict combined strategy of phytochemical and lipid inhibition is applied:

First, EPA and DHA act as competitive inhibitors. Under conditions of cell membrane damage (due to oxidative stress) and an excess of intracellular calcium, there is an upregulation of phospholipase A2 (PLA2) and cyclooxygenase-2 (COX-2) transcription, leading to an explosive increase in the production of arachidonic acid (AA) metabolites. EPA competes with AA for these very same enzymes. Changing the n-6:n-3 ratio in favor of EPA leads to the production of eicosanoids with significantly lower inflammatory activity, as well as the synthesis of potent anti-inflammatory mediators such as E-series resolvins. In experiments on aged rats (22 months), an EPA-enriched diet successfully prevented age-related increases in cortical and hippocampal IL-1$\beta$ and IL-4, and two months of EPA/DHA treatment prevented astrocyte morphological changes and reversed spatial memory deficits.

Second, curcumin in synergy with piperine is integrated into the protocol. Curcumin has a proven ability to inhibit pro-inflammatory cytokines, reduce inflammation markers, and modulate neurotransmitters (serotonin, dopamine, and norepinephrine). Furthermore, curcumin and its derivatives significantly accelerate BDNF gene expression. However, the fundamental problem with isolated curcumin is its critically low permeability in vitro and in vivo, along with rapid glucuronidation in the liver, which minimizes its bioavailability. The addition of piperine (a black pepper alkaloid) acts as a bioavailability enhancer. Clinical and preclinical data show that piperine can increase curcumin absorption and serum concentration by up to 2000% without any side effects.

In mouse studies, the co-administration of curcumin and piperine at a fixed 1:1 ratio of their effective doses (ED50) demonstrated a potent synergistic effect. This combination promotes anti-inflammatory responses and the upregulation of neurotrophic factors (BDNF and CREB), which is critically important for oligodendrocyte survival and remyelination following neuroinflammatory damage. The combination also protects against haloperidol-induced neurotoxicity and exhibits high inhibitory activity against acetylcholinesterase (AChE), further supporting cognitive functions.

Phase 2: Intracellular Signaling, NMDAR Upregulation, and Phytochemical Induction (T-minus 6 weeks)

Once the structural reorganization of the phospholipid bilayer is initiated and the systemic inflammatory background is reduced, it is necessary to activate the intracellular signaling cascades directly responsible for regulating synaptic density. The formation of new dendritic spines requires a massive energy potential and specific intracellular messengers. The key molecular agent at this stage is magnesium; however, its delivery requires overcoming significant blood-brain barriers.

Magnesium L-Threonate (MgT): Overcoming the BBB and Synaptogenesis

Standard forms of magnesium widely available on the market (magnesium oxide, chloride, hydroxide, or citrate) have an extremely low ability to penetrate the blood-brain barrier. They act predominantly in the periphery, causing muscle relaxation, improving digestion, or exerting a laxative effect (especially oxide and hydroxide), but do not reach neuronal tissues in concentrations sufficient to induce plasticity. To ensure central synaptogenic neuroplasticity, the use of Magnesium L-threonate (MgT, L-TAMS, commercial name Magtein) is required.

The uniqueness of Magnesium L-threonate lies in the fact that the threonate molecule itself (which is naturally present in cerebrospinal fluid) utilizes glucose transporters (GLUT) for direct, targeted penetration into neurons. In cultures of hippocampal neurons and neurons derived from human neural stem cells, it has been proven that treatment with threonate directly induces an increase in intracellular $Mg^{2+}$ concentration, whereas other common magnesium anions do not produce a similar effect.

The accumulation of intracellular $Mg^{2+}$ ions plays the role of a critical signaling node that acts as a biomarker and regulator of the density of functional synapses and branch-specific synaptic computations. Therapeutic elevation of brain magnesium levels through oral MgT intake leads to a series of fundamental neurobiological restructurings:

• Specific upregulation of the expression of NMDA receptors containing the NR2B subunit. These receptors play a central role in controlling synaptic plasticity and inducing long-term potentiation (LTP). The enhanced membrane fluidity achieved in Phase 1 via DHA creates an optimal lipid microenvironment for the successful integration of these new receptor complexes into the postsynaptic membrane.
• Boosting the mitochondrial membrane potential ($\Delta\Psi_m$), which provides neurons with a local energy reserve (ATP) strictly necessary for the energy-intensive process of synaptogenesis and dendritic branching.
• Inhibition of calcineurin hyperactivation. Elevating extracellular magnesium prevents the loss of synaptic NMDARs caused by high levels of toxic amyloid-beta (A$\beta$). In addition, magnesium stabilizes the expression of the BACE1 enzyme and reliably reduces the production of toxic peptides sAPP$\beta$ and $\beta$-CTF.

Impressive results have been obtained in APPswe/PS1dE9 transgenic mice (an Alzheimer's disease model). MgT treatment proved capable of reversing memory deficits and halting synaptic loss even when initiated at the end-stage of the disease's pathological progression, tested in mice aged 23 months (after treatment lasting from 1 to 17 months). In human clinical trials, MgT supplementation led to significant improvements in global cognitive abilities in older adults, patients with mild cognitive impairment (MCI), and attention deficit hyperactivity disorder (ADHD). Successful cases show the achievement of perfect scores (30/30) on SLUMS cognitive tests following integrative therapy including MgT.

MgT Dosing Protocol in Priming: To translate the minimum effective dose from animal models (75 mg/kg/day elemental magnesium for mice, equivalent to 910 mg/kg/day MgT; or 50 mg/kg/day elemental magnesium for rats) to humans, standardized protocols are applied. The European Food Safety Authority (EFSA) and clinical practice recommend a total dose of 1500 to 2000 mg of MgT per day (which contains approximately 144–200 mg of elemental magnesium). Achieving structural changes in synapses takes time. Tangible cognitive effects appear after 4–6 weeks of continuous supplementation. Given this, the phase starts 6 weeks prior to the main event. Intake should be divided:

• Morning (with breakfast): 1000 mg MgT. Ensures a stable level of intracellular magnesium to support cognitive functions throughout the day.
• Afternoon (with lunch): 500 mg MgT.
• Evening: Possible intake of the remaining 500 mg MgT (if it does not cause overly vivid dreams) or substitution with 200-300 mg of magnesium glycinate 30-60 minutes before sleep to support parasympathetic relaxation and memory consolidation.

Phytochemical Induction of Neurotrophic Cascades

Parallel to magnesium accumulation, phytochemical compounds—plant flavonoids, terpenoids, alkaloids, and polyphenolic compounds—are introduced into the protocol. They act not merely as antioxidants, but as epigenetic regulators and activators of complex signaling pathways, including GSK-3$\beta$, MAPK/ERK, PI3K/Akt/mTOR, CREB, and Wnt/$\beta$-catenin, which ultimately stimulate BDNF gene expression. Coffee fruit extracts and pure caffeine have demonstrated the in vitro ability to effectively stimulate the expression of BDNF protein isoforms I and IV in cortical neurons in the presence of depolarizing agents (such as 10 mM KCl). In vivo, these extracts reliably increase plasma BDNF concentrations in healthy individuals. Polyphenols, such as resveratrol and olive pomace extracts (10 mg/kg), are classified as Calorie Restriction Mimetics (CRMs). They mimic the effects of fasting by activating sirtuins, AMPK, and autophagy, while significantly increasing BDNF protein levels in the hippocampus and olfactory bulbs, promoting neuroprotection, and inhibiting apoptosis in animal models of neurodegeneration. These substances "warm up" the transcriptional apparatus of neurons, preparing it for an explosive synthesis of proteins in the next phase.

Phase 3: Metabolic Switch and Intensive Cardio-Priming (T-minus 14 days)

By the beginning of this phase (two weeks before the targeted intervention), the cellular substrate possesses restored membrane fluidity, reduced pro-inflammatory cytokine levels, high NMDAR density, and sufficient energy potential. The time arrives to induce a massive, systemic release of endogenous neurotrophic factors (BDNF, VEGF, IGF-1) and remodel the microcirculatory bed. The optimal tool for this is combined physical-metabolic stress.

The Synergy of High-Intensity Interval Training (HIIT) and Muscle Contraction Metabolites

Physical exercise stimulates architectural remodeling primarily through the release of circulating factors—metabolites and proteins from muscles (myokines), the liver, and bone tissue (e.g., osteocalcin)—which cross the BBB and converge in the hippocampus to activate BDNF signaling. The key variable here is intensity. Short bouts of high-intensity interval training (HIIT) provide a BDNF increase that significantly surpasses the effects of intense continuous training. The increased number of powerful skeletal muscle contractions stimulates the secretion of the muscle membrane protein FNDC5 (a precursor of the myokine irisin), which acts as a proven direct positive regulator of brain BDNF levels.

Additionally, when crossing the anaerobic threshold (lactate threshold), lactate is produced and freely transported across the BBB. Lactate acts in the brain not only as an alternative and highly efficient energy source for astrocytes and neurons but also as a powerful signaling molecule (epigenetic regulator) directly triggering neuroplastic cascades.

To prevent the depletion of the body's antioxidant systems and avoid overtraining, cardio-priming protocols must be strictly dosed. A mouse model of a 1-week HIIT training (comprising sprints at 130% maximum velocity, $V_$, interspersed with moderate running at 60% $V_$) showed brilliant results. Just a week of such exertion increased markers of proliferation (MCM2), neurogenesis (Doublecortin, DCX), mitochondrial density (VDAC), and BDNF, while concurrently reducing the level of mitochondrial superoxide dismutase 2 (SOD2) in the hippocampus. Critically, this HIIT protocol did not cause an increase in hydrogen peroxide ($H_2O_2$) production or the concentration of carbonylated proteins (markers of oxidative damage) in the dentate gyrus. During this period, the intake of potent exogenous antioxidants may be counterproductive. Reactive oxygen species (ROS) generated by mitochondria in small doses during exercise act via hormesis, serving as necessary signaling molecules for the adaptive transcription of survival genes. Blocking this signal with high doses of vitamins C or E can blunt exercise-induced neuroplasticity.

14-Day Clinical Cardio-Priming Protocol

Based on translational clinical data from the EXPRESS study and protocols for preparing for motor learning (balancing tasks), a 14-day period of aerobic priming induces reliable and MRI-visualizable changes. In a study examining a complex Dynamic Balancing Task (DBT—maintaining a horizontal position on a dynamometer platform with an accuracy of ±3° for 30 seconds without visual feedback), the application of priming led to immediate structural modifications. Group differences in white matter structure beneath primary sensorimotor areas, as well as changes in the amplitude of low-frequency fluctuations (ALFF) in adjacent gray matter (reflecting spontaneous neural activity at rest), were captured on MRI immediately after two weeks of cardio-priming, even before the motor learning itself began.

Training Session Structure: Intensity is individualized based on physical working capacity at heart rates of 120 bpm ($PWC_{120}$) and 170 bpm ($PWC_{170}$). 7 training sessions are performed over 2 weeks.

• Week 1 (Duration 19 minutes): Warm-up 5 min of continuous cycling at $PWC_{120} \rightarrow$ 3-minute phase with gradual intensity increase (6 steps of 30 sec) up to 100% individual $PWC_{170} \rightarrow$ 4 min active recovery at $PWC_{120} \rightarrow$ second 3-minute phase of stepped increase to $PWC_{170} \rightarrow$ cool-down 4 min at $PWC_{120}$. Lactate monitoring showed that its average concentration during the workout was 44.48% above the individual anaerobic threshold (IAT).
• Week 2 (Duration 21 minutes): To prevent a habituation effect that could diminish the neuroplastic response, the total session duration is increased by 2 minutes by prolonging the time spent at peak intensity.

Analytical Note for Laboratory Control: When measuring circulating BDNF levels, it must be noted that its concentration in serum is approximately 14 times higher than in plasma due to the release of the factor from platelets during coagulation. Prolonging blood clotting time up to 30–60 minutes in vitro can substantially increase measurable BDNF levels. BDNF levels typically return to baseline values within a few hours after physical exertion. Environmental affordances, such as outdoor walking or taking the stairs, also make a moderate contribution to basal BDNF levels.

Metabolic Shift: Ketosis and Intermittent Fasting

To maximize BDNF expression, the exercise protocol is synchronized with Intermittent Fasting (IF). The combination of intense exercise and periods of food deprivation creates a unique synergistic stressor that forces the brain to execute a "metabolic shift" (cerebral substrate switch). The brain transitions from the exclusive use of glucose to the utilization of ketone bodies produced by the liver, particularly $\beta$-hydroxybutyrate.

$\beta$-hydroxybutyrate acts as an endogenous histone deacetylase (HDAC) inhibitor. By suppressing deacetylation, it epigenetically "unwinds" chromatin, opening access for transcription factors to the BDNF gene promoters, thereby radically enhancing its expression. Furthermore, this metabolic shift stimulates the PI3K, Akt, and mTOR pathways and inhibits the inflammatory NF-$\kappa$B pathway, which triggers autophagy—the process of cellular clearance of damaged organelles, absolutely essential for healthy neurogenesis (NSPAN).

Amplification via Thermoregulatory Stress (Sauna)

Immediately after completing the HIIT session (post-workout), the protocol prescribes exposure to intense heat stress (e.g., a Finnish sauna). Physiologically, heat stress acts as a "cardiovascular mimicry." Extreme heat forces the heart to beat faster and peripheral and cerebral blood vessels to dilate (vasodilation), which imitates the effects of moderate aerobic exercise and improves endothelial function by increasing nitric oxide bioavailability.

Using the sauna immediately after exercise prolongs the so-called "cardiovascular drift," artificially extending the temporal window of elevated cerebral blood flow and nutrient delivery to the brain, but without the mechanical exhaustion and muscle fiber damage characteristic of continuing physical exertion.

From the perspective of molecular plasticity, hyperthermia:

• Provides a synergistic upregulation and release of BDNF, which is often described as "Miracle-Gro" for neurons.
• Potently stimulates the transcription of Heat Shock Proteins (HSPs). These chaperones play a crucial role in the refolding of damaged proteins, protecting neurons from stress and apoptosis under high metabolic load.
• Promotes a shift of the autonomic nervous system from the dominant sympathetic phase (excitation during HIIT) to deep parasympathetic activity (rest and digest) during the subsequent cooling, acting as a trigger for launching glymphatic clearance mechanisms.

Phase 4: Glymphatic Optimization and Sleep Architecture (Continuous, focus on T-minus 14 days)

Neuroplasticity is a resource-intensive bidirectional process. It requires not only the induction of synaptic growth but also the massive clearance (pruning) of irrelevant connections. During active metabolism induced by priming, a vast amount of protein waste and neurotoxic metabolites is generated in the brain's extracellular space.

The clearance of the interstitial space of the central nervous system is governed by the glymphatic system—the macroscopic analog of the body's lymphatic system, discovered only in the last decade. Glymphatic flow washes through brain tissue, flushing out toxic aggregates (such as amyloid-beta and tau protein). The efficiency of this pump system fundamentally depends on astrocyte morphology, specifically the polarization and correct localization of specialized water channels—aquaporin-4 (AQP4)—on astroglial endfeet that tightly encircle cerebral vessels. Aging or neuroinflammation lead to the loss of AQP4 localization, which in older mice manifests as an 80–90% reduction in glymphatic activity and a 40% drop in amyloid-beta clearance rate. Thus, structural suppression of astrogliosis using Omega-3 (Phase 1) is an absolute prerequisite for the functioning of Phase 4.

The primary driver of the glymphatic pump is deep sleep, particularly Slow-Wave Sleep (SWS, or stage N3). Studies show that it is during N3 that a physiological drop in central noradrenergic tone occurs. Astrocytes, sensitive to norepinephrine, alter the concentration of extracellular ions, resulting in a 60% expansion of the interstitial fluid space volume. This expansion lowers hydrodynamic resistance and allows for a massive discharge of waste into the perivascular spaces for elimination from the skull.

Protocol for Maximizing Glymphatic Clearance:

• Ensuring SWS Continuity: Any micro-arousals caused by clinical seizures, interictal epileptiform discharges (IEDs), or sleep-disordered breathing destroy SWS architecture. Obstructive sleep apnea (OSA), diagnosed by the apnea-hypopnea index (AHI) on polysomnography, or central sleep apnea radically reduces glymphatic clearance efficiency.
• Physical Drivers: Arterial wall pulsation, low-frequency deep breathing events, and vasomotion act as mechanical pumps propelling glymphatic fluid.
• Synchronization with Supplements: Evening intake of Magnesium L-threonate or magnesium glycinate modulates GABA receptors, reducing glutamatergic excitability and increasing the proportion of deep sleep stages (SWS and REM).

Phase 5: Neuroendocrine Calibration and Receptor Modulation (T-minus 7 days to intervention)

Approaching the zero point (T-0)—the moment of administering a potent neuroplasticity trigger (e.g., a psychoplastogen therapy session, the start of an intensive INHANCE rehabilitation program, or rTMS/tDCS stimulation priming)—the physiology must be finely calibrated at the receptor and endocrine levels. Critical attention during this week is paid to glucocorticoid (cortisol) dynamics and the sensitivity of the $5-HT_{2A}$ serotonin receptor.

The Biphasic Role of Glucocorticoids (Cortisol/Corticosterone)

The interaction of stress hormones and plasticity mechanisms is strictly dichotomous and non-linear. Inadequate understanding of this axis often leads to the failure of clinical interventions.

1. Acute, Resolvable Glucocorticoid Peak as a Plasticity Driver: Fundamental research in mice shows that to realize post-acute anxiolytic and psychoplastogenic effects (e.g., after the administration of 3 mg/kg psilocybin), a transient, acute burst of corticosterone is absolutely necessary. This acute cortisol burst triggers specific molecular cascades in the prefrontal cortex and hippocampus. Experimental suppression of this acute peak—by prior administration of mifepristone (a glucocorticoid receptor antagonist) or artificial suppression of the adrenal response—completely blunted anxiolytic behavior in mice, measured 4 hours post-intervention. Similar plastic effects were achieved simply through controlled stress-induced glucocorticoid release without psychedelics.
2. Chronic Glucocorticoid Elevation as a Plasticity Inhibitor: Conversely, if the brain is exposed to a trigger against a backdrop of preexisting, unresolved chronic stress (passive oral exposure to 80 µg/ml corticosterone for 21 days), long-term neuroplastic benefits are completely annihilated. Chronic exposure to high cortisol doses causes profound suppression of the hypothalamic-pituitary-adrenal (HPA) axis via a negative feedback mechanism. A suppressed HPA axis physically loses the ability to generate that essential "acute peak" in response to trigger administration. Consequently, the intervention's ability to reduce anxiety (e.g., lower latency to feed) and form new neural pathways is blocked for up to 7 days post-session.

Practical Application: For 7–14 days prior to T-0, the patient must be shielded from sources of chronic psychological, social, or toxic stress. Reducing the overall allostatic load (through meditative practices, decreasing workloads, and using cortisol-modulating herbal adaptogens like ashwagandha) is necessary not merely for psychological comfort, but to restore the biochemical reactivity of the HPA axis to ensure the acute cortisol peak at the moment of intervention.

5-HT2A Receptor Sensitization and TrkB Allosteric Modulation

The $5-HT_{2A}$ receptor, most densely expressed in cortical layer V of the brain, is a central biochemical node integrating neurotrophic signals, energy metabolism, and psychoplastogenic effects. Classic psychedelic triggers (psilocybin/psilocin, DMT, LSD) exert their profound structural effects (growth of dendritic complexity, formation of new spines) via the activation of this receptor. Furthermore, studies show that activation of neuronal $5-HT_{2A}$ induces large-scale metabolic reprogramming, including receptor-dependent upregulation of the tricarboxylic acid (TCA) cycle and the interconversion of critical amino acids (lysine, glutamine, asparagine, and aspartate), linking serotonin transmission with increased lifespan and energy homeostasis.

The sensitivity and density of $5-HT_{2A}$ receptors are labile and subject to potent regulation by nutrients and pharmacology:

• Nutrient Sensing and Protein Restriction: A surprising discovery in basic neurobiology is that the $5-HT_{2A}$ receptor functions as a nutrient availability sensor. Mutant models (Drosophila melanogaster) lacking the $5-HT_{2A}$ receptor show a paradoxical resistance to dietary protein variations that typically shorten lifespan. Chronic reduction of protein intake leads to an adaptive physiological response—the brain attempts to compensate for a perceived "inability to meet demand" by sensitizing serotonin pathways to stimulate the motivation to forage for protein. Employing short-term protein restriction in Phase 5 may heighten the receptor apparatus's sensitivity before ligand administration.
• Elimination of Inhibitors and Competitive Ligands: To avoid pharmacological downregulation of $5-HT_{2A}$ receptors, paradoxical trafficking, and to prevent dangerous serotonin syndrome, it is imperative to strictly eliminate all agents that artificially boost endogenous serotonin 1-2 weeks beforehand. These include:
  1. SSRIs (e.g., escitalopram): Inhibiting the SERT transporter causes massive compensatory downregulation of postsynaptic $5-HT_{2A}$ receptors, negating the response to psychoplastogens.
  2. Serotonin Precursors (L-Tryptophan, 5-HTP): Elevate basal serotonin, creating competition for receptors and increasing toxicity risk.
  3. St. John's Wort (hyperforin), SAMe, and Lithium: Exert weak MAO-inhibitory effects and modulate monoamine reuptake, unpredictably distorting the receptor landscape and hepatic cytochrome (CYP) activity.
  4. 5-HT2A Antagonists: Drugs like ketanserin, trazodone (SARIs), or typical antipsychotics directly block the receptor, acting as "trip killers" and entirely nullifying the psychoplastogenic and subjective effects of the molecules.

A paramount molecular discovery in recent years is the fact that psychoplastogens can induce neuroplasticity not only through $5-HT_{2A}$ but also via a direct, serotonin-independent mechanism. In vitro and in vivo experiments have proven that LSD and psilocin directly bind to the transmembrane domain of the TrkB receptor (the cognate receptor for BDNF) with high affinity (LSD $K_i$ = 3.38 nM; Psilocin $K_i$ = 673 nM). Binding to TrkB, these substances act as positive allosteric modulators (PAMs). They induce rapid and sustained TrkB receptor dimerization (which is not blocked by ketanserin) and exponentially potentiate the effect of even extremely low endogenous BDNF doses. The Y433F receptor mutation completely blocks this binding effect. This discovery perfectly concludes the architecture of biological priming: the vast pool of endogenous BDNF accumulated thanks to HIIT and sauna exposure (Phase 3) receives the maximum transcriptional response due to the psychoplastogen's direct action on the allosterically sensitized TrkB receptor in Phase 6.

Phase 6: Induction, Window of Critical Plasticity, and Structural Consolidation (T-0 and beyond)

The application of the targeted trigger (be it an intensive 10-week computerized cognitive training protocol targeting cholinergic signaling, rTMS/tDCS stimulation priming, or pharmacological induction via psychoplastogens) against the backdrop of a prepared physiological substrate leads to the opening of a phenomenon known as the "window of critical plasticity."

In the adult brain, critical periods—time intervals when neural networks are hypersusceptible to environmental experience (akin to a child's brain)—are rigidly closed by physical and biochemical barriers, including inhibitory networks of parvalbumin-expressing (PV) fast-spiking interneurons and perineuronal nets. Induced priming temporarily dissolves these barriers. Laboratory studies evaluating social learning (forming associations between an environment and a social reward) using modulator molecules show that the duration of this open state of critical plasticity strictly depends on the specific agent and correlates with the duration of its acute subjective effects in humans:

• For ketamine, the window of social and structural learning remains open for a relatively short time—about 48 hours.
• For psilocybin, the open state is sustained for two full weeks (up to 14 days).
• For MDMA—two weeks.
• For LSD—three weeks.
• For ibogaine—up to four weeks.

Managing Cognitive Flexibility and Environment (Set and Setting): During this critical two- or three-week period, the brain is in a hypersensitive state characterized by unprecedented cognitive flexibility—the ability to seamlessly shift between paradigms, tolerate uncertainty, and update beliefs based on new information. An explosive formation of new synapses occurs, marked by increased radioligand binding to synaptic vesicle glycoprotein 2A (SV2A) on positron emission tomography. In mouse models, this period witnesses intensified dendritic spine formation in the medial prefrontal cortex and a reduction in the time required to extinguish conditioned fear.

It is critically important clinically to recognize that biological plasticity is neutral—it carries no "plus" or "minus" sign. It simply reflects substrate malleability. Exposure to a negative, stressful, traumatic, or impoverished environment during this period will lead to the rapid fixation of maladaptive, depressive patterns (the phenomenon of negative neuroplasticity), exacerbating degenerative changes. Therefore, the integration phase must unfold in a supportive therapeutic environment with targeted skill training. During this phase, heavy physiological stressors are discontinued (e.g., intensive HIIT is replaced by mild aerobic recovery exercise), while support for membrane fluidity (Omega-3 DHA) and the constant provision of building materials and energy for synaptogenesis (Magnesium L-threonate 1500 mg/day) continues.

Summarizing Architecture: Chronological Matrix of Biological Priming

The structuring of neurobiological data into a unified chronological model is presented below. The protocol considers the zero point (T-0) as the moment of administering the primary neuroplasticity trigger.

Conclusion

An exhaustive analysis of open translational and fundamental neurobiological data unequivocally demonstrates that enhancing neuroplasticity is not the result of monotherapeutic, isolated exposure. It is a complex, resource-intensive, multifactorial cascade requiring precise, sequential systemic tuning.

The developed working scheme of biological priming shifts the clinical focus from manipulating the final trigger to the meticulous preparation of the cellular and systemic foundation. Without adequate membrane fluidity provided by prolonged docosahexaenoic acid (DHA) saturation, receptor modulations and quantum signal transfer lose effectiveness. Without resolving reactive astrogliosis and morphologically normalizing glymphatic clearance (AQP4 aquaporins), the release of endogenous BDNF is completely negated by a pro-inflammatory microenvironment and toxic interstitial waste. In turn, without intensive aerobic cardio-priming (HIIT protocols at $PWC_{170}$) and epigenetic ketosis ($\beta$-hydroxybutyrate), the brain physically fails to form a sufficient pool of neurotrophic factors to support large-scale dendritic structural branching. Finally, without fine calibration of the endocrine HPA axis (restoring the capacity for an acute, resolvable cortisol peak) and the receptor apparatus (allosteric sensitization of $5-HT_{2A}$ and TrkB), even the most potent molecular trigger cannot realize its full psychoplastogenic potential.

Strict integration of the described 6 priming phases allows clinicians and researchers to minimize the catastrophic risks of "negative plasticity" and opens a profoundly manageable therapeutic window (lasting from 48 hours to 3-4 weeks). This paradigm establishes a robust physiological substrate for sustained modifications of neural architecture, equally effective in rehabilitation post-traumatic brain injuries and ischemic strokes, as well as in treating resistant psychiatric (MDD, PTSD) and degenerative disorders. The implementation of such multimodal, chronologically precise protocols into evidence-based medical practice holds the potential to exponentially surpass the efficacy of existing fragmented methods for restoring cognitive reserve.